Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing

[1]  M. Pirmohamed,et al.  Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy , 2009, Pharmacogenetics and genomics.

[2]  P. Deloukas,et al.  Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study , 2009, Pharmacogenetics and genomics.

[3]  D. Roden,et al.  Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. , 2009, Blood.

[4]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[5]  Eun-Young Kim,et al.  Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement , 2009, Pharmacogenetics and genomics.

[6]  Panos Deloukas,et al.  The largest prospective warfarin-treated cohort supports genetic forecasting. , 2009, Blood.

[7]  B. Gage,et al.  Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation , 2009, Annals of Internal Medicine.

[8]  Nianjun Liu,et al.  VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. , 2008, Pharmacogenomics.

[9]  R. Barrack,et al.  Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients , 2008, Journal of thrombosis and haemostasis : JTH.

[10]  C. Thorn,et al.  Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African Americans , 2008, Clinical pharmacology and therapeutics.

[11]  M. Rieder,et al.  Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin , 2008, Clinical pharmacology and therapeutics.

[12]  W. Sadee,et al.  Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. , 2008, Blood.

[13]  Mark Crowther,et al.  Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[14]  J. Hirsh,et al.  Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[15]  A. Lincoff,et al.  Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[16]  Y. Turpaz,et al.  CYP4F2 genetic variant alters required warfarin dose. , 2008, Blood.

[17]  Henrik Druid,et al.  Incidence of fatal adverse drug reactions: a population based study. , 2008, British journal of clinical pharmacology.

[18]  L. Alfredsson,et al.  Incidence and predictors of severe bleeding during warfarin treatment , 2008, Journal of Thrombosis and Thrombolysis.

[19]  D. Pollock,et al.  National surveillance of emergency department visits for outpatient adverse drug events in children and adolescents. , 2008, The Journal of pediatrics.

[20]  J. Carlquist,et al.  Warfarin pharmacogenetics: up close and personalized , 2008 .

[21]  G. Mcgwin,et al.  Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African‐American and European‐American Patients on Warfarin , 2008, Clinical pharmacology and therapeutics.

[22]  Margaret Piper,et al.  A Rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding , 2008, Genetics in Medicine.

[23]  Marc S. Williams,et al.  Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin , 2008, Genetics in Medicine.

[24]  E. Hylek,et al.  Genetic Testing for Warfarin Dosing? Not Yet Ready for Prime Time , 2008, Pharmacotherapy.

[25]  B. Horne,et al.  Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation , 2007, Circulation.

[26]  Deepak Voora,et al.  Genetic-based dosing in orthopedic patients beginning warfarin therapy. , 2007, Blood.

[27]  Alan H B Wu,et al.  Use of genetic and nongenetic factors in warfarin dosing algorithms. , 2007, Pharmacogenomics.

[28]  D. Wysowski,et al.  Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. , 2007, Archives of internal medicine.

[29]  B. Horne,et al.  Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study , 2006, Journal of Thrombosis and Thrombolysis.

[30]  M. Pirmohamed.  Warfarin: almost 60 years old and still causing problems. , 2006, British journal of clinical pharmacology.

[31]  D. Pollock,et al.  National surveillance of emergency department visits for outpatient adverse drug events. , 2006, JAMA.

[32]  V. Dolžan,et al.  The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement , 2006, Thrombosis and Haemostasis.

[33]  Julie A. Johnson,et al.  Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements , 2006, Clinical pharmacology and therapeutics.

[34]  E. Butchart,et al.  Increased Sensitivity to Warfarin After Heart Valve Replacement , 2006, The Annals of pharmacotherapy.

[35]  Peter Wood,et al.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.

[36]  M. Charng,et al.  A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. , 2005, Human molecular genetics.

[37]  Deborah A Nickerson,et al.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[38]  Mark Crowther,et al.  Systematic overview of warfarin and its drug and food interactions. , 2005, Archives of internal medicine.

[39]  M. Verny,et al.  Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen. , 2005, American Journal of Medicine.

[40]  M. Margaglione,et al.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. , 2005 .

[41]  M. Caldwell,et al.  Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. , 2004, Pharmacogenetics.

[42]  Howard L McLeod,et al.  Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin , 2003, Thrombosis and Haemostasis.

[43]  D. Anderson,et al.  Comparison of 10-mg and 5-mg Warfarin Initiation Nomograms Together with Low-Molecular-Weight Heparin for Outpatient Treatment of Acute Venous Thromboembolism , 2003, Annals of Internal Medicine.

[44]  Kibong Kim,et al.  Factors Affecting Warfarin Therapy following Cardiac Valve Surgery , 2002, The Annals of pharmacotherapy.

[45]  David L Veenstra,et al.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.

[46]  M. Margaglione,et al.  Genetic Modulation of Oral Anticoagulation with Warfarin , 2000, Thrombosis and Haemostasis.

[47]  W. Ageno,et al.  Exaggerated initial response to warfarin following heart valve replacement. , 1999, The American journal of cardiology.

[48]  J. Hirsh,et al.  A randomized trial comparing 5-mg and 10-mg warfarin loading doses. , 1999, Archives of internal medicine.

[49]  J. Hirsh,et al.  Comparison of 5-mg and 10-mg Loading Doses in Initiation of Warfarin Therapy , 1997, Annals of Internal Medicine.

[50]  J. Carroll.  Heparin-induced increase in the International Normalized Ratio. , 1996, American journal of clinical pathology.

[51]  H. M. Solomon,et al.  Heparin-induced increase in the international normalized ratio. Responses of 10 commercial thromboplastin reagents. , 1995, American journal of clinical pathology.

[52]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[53]  D. DuBois,et al.  A formula to estimate the approximate surface area if height and weight be known , 1989 .

[54]  D. D. Bois,et al.  CLINICAL CALORIMETRY: TENTH PAPER A FORMULA TO ESTIMATE THE APPROXIMATE SURFACE AREA IF HEIGHT AND WEIGHT BE KNOWN , 1916 .

[55]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[56]  S. Hunt,et al.  Common VKORC1 and GGCX polymorphisms associated with warfarin dose , 2005, The Pharmacogenomics Journal.

[57]  M. Nydahl,et al.  Five-day food intake in elderly female outpatients with Parkinson's disease, rheumatoid arthritis or stroke. , 2004, The journal of nutrition, health & aging.

[58]  O. Wallerman,et al.  Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors , 2004, The Pharmacogenomics Journal.